IL6 and Autoimmunity: We show for the first time that LIFNano-CD4 (i) cross the BBB; (ii) reduce pathogenic levels of IL-6 that accumulate behind the BBB during demyelinating autoimmunity; and (iii) are non-toxic at efficacious i.v. doses in a formal preclinical SAD trial.